Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06099704

Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis — CANDID  

Moderate to Severe Atopic Dermatitis Clinical Trial

Official title:
A Prospective, Observational Study of Canadian Patients Receiving Dupixent® for Moderate to Severe Atopic Dermatitis

Clinical Trial Summary

This is a prospective, 18-month observational study of adult, adolescent and pediatric Canadian participants with Atopic Dermatitis (AD) commonly known as Eczema, who receive treatment with Dupixent for moderate-to-severe AD (msAD) according to the Canadian-specific prescribing information (in accordance with the Canadian Dupixent Product Monograph). The study will be conducted in approximately 30 centers in Canada to assess participants of all ethnicities and races. At each participating site, all AD participants who receive an initial prescription for Dupixent will be invited to participate in this study, until the Canadian enrollment goal is achieved.

Clinical Trial Description

The duration of the study for each participant will be of 18 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06099704
Study type Observational
Source Sanofi
Contact Trial Transparency email recommended (Toll free for US & Canada)
Phone 800-633-1610
Email Contact-US@sanofi.com
Status Recruiting
Phase
Start date October 10, 2023
Completion date April 10, 2026
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06012812 - A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT05549947 - Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis Phase 2
Recruiting NCT06136741 - A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT03568162 - Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT00148746 - Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis N/A
Recruiting NCT05702268 - Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis Phase 2
Recruiting NCT05997927 - Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis Phase 2
Not yet recruiting NCT05197023 - A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS Phase 1
Not yet recruiting NCT06239311 - Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. Phase 3
Terminated NCT01286220 - Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis N/A
Completed NCT02426359 - Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients Phase 2